SEC Filing 10-K: AbbVie Inc.
February 19, 2016 12:35pm EST
Source: SEC (Index ) via Sqoop
Form 10-K
Exhibits
10.4
a2227341zex-10_4.htm
10.5
a2227341zex-10_5.htm
10.6
a2227341zex-10_6.htm
10.8
a2227341zex-10_8.htm
12
a2227341zex-12.htm
21
a2227341zex-21.htm
23
a2227341zex-23.htm
31.1
a2227341zex-31_1.htm
31.2
a2227341zex-31_2.htm
32.1
a2227341zex-32_1.htm
32.2
a2227341zex-32_2.htm
101.INS
abbv-20151231.xml
101.SCH
abbv-20151231.xsd
101.CAL
abbv-20151231_cal.xml
101.DEF
abbv-20151231_def.xml
101.LAB
abbv-20151231_lab.xml
101.PRE
abbv-20151231_pre.xml
XBRL Reports
R1
Document and Entity Information
R2
Consolidated Statements of Earnings
R3
Consolidated Statements of Earnings (Parenthetical)
R4
Consolidated Statements of Comprehensive Income
R5
Consolidated Statements of Comprehensive Income (Parenthetical)
R6
Consolidated Balance Sheets
R7
Consolidated Balance Sheets (Parenthetical)
R8
Consolidated Statements of Equity
R9
Consolidated Statements of Cash Flows
R10
Background and Basis of Presentation
R11
Summary of Significant Accounting Policies
R12
Supplemental Financial Information
R13
Earnings Per Share
R14
Licensing, Acquisitions and Other Arrangements
R15
Collaboration with Janssen Biotech, Inc.
R16
Goodwill and Intangible Assets
R17
Restructuring Plans
R18
Debt, Credit Facilities, and Commitments and Contingencies
R19
Financial Instruments and Fair Value Measures
R20
Post-Employment Benefits
R21
Equity
R22
Income Taxes
R23
Legal Proceedings and Contingencies
R24
Segment and Geographic Area Information
R25
Quarterly Financial Data (unaudited)
R26
Summary of Significant Accounting Policies (Policies)
R27
Summary of Significant Accounting Policies (Tables)
R28
Supplemental Financial Information (Tables)
R29
Licensing, Acquisitions and other Arrangements (Tables)
R30
Goodwill and Intangible Assets (Tables)
R31
Restructuring Plans (Tables)
R32
Debt, Credit Facilities, and Commitments and Contingencies (Tables)
R33
Financial Instruments and Fair Value Measures (Tables)
R34
Post-Employment Benefits (Tables)
R35
Equity (Tables)
R36
Income Taxes (Tables)
R37
Segment and Geographic Area Information (Tables)
R38
Quarterly Financial Data (unaudited) (Tables)
R39
Background and Basis of Presentation (Details)
R40
Summary of Significant Accounting Policies (Details)
R41
Summary of Significant Accounting Policies (Details 2)
R42
Summary of Significant Accounting Policies (Details 3)
R43
Supplemental Financial Information (Details)
R44
Earnings Per Share (Details)
R45
Licensing, Acquisitions and Other Arrangements (Details)
R46
Licensing, Acquisitions and Other Arrangements (Details 2)
R47
Licensing, Acquisitions and Other Arrangements (Details 3)
R48
Collaboration with Janssen Biotech, Inc. (Details)
R49
Goodwill and Intangible Assets (Details)
R50
Goodwill and Intangible Assets (Details 2)
R51
Restructuring Plans (Details)
R52
Restructuring Plans (Details 2)
R53
Debt, Credit Facilities, and Commitments and Contingencies (Details)
R54
Debt, Credit Facilities, and Commitments and Contingencies (Details 2)
R55
Financial Instruments and Fair Value Measures (Details)
R56
Financial Instruments and Fair Value Measures (Details 2)
R57
Financial Instruments and Fair Value Measures (Details 3)
R58
Financial Instruments and Fair Value Measures (Details 4)
R59
Financial Instruments and Fair Value Measures (Details 5)
R60
Financial Instruments and Fair Value Measures (Details 6)
R61
Financial Instruments and Fair Value Measures (Details 7)
R62
Post-Employment Benefits (Details)
R63
Post-Employment Benefits (Details 2)
R64
Post-Employment Benefits (Details 3)
R65
Equity (Details)
R66
Equity (Details 2)
R67
Equity (Details 3)
R68
Equity (Details 4)
R69
Income Taxes (Details)
R70
Income Taxes (Details 2)
R71
Income Taxes (Details 3)
R72
Income Taxes (Details 4)
R73
Legal Proceedings and Contingencies (Details)
R74
Segment and Geographic Area Information (Details)
R75
Segment and Geographic Area Information (Details 2)
R76
Quarterly Financial Data (unaudited) (Details)